Exploring the association of disease-modifying therapies for multiple sclerosis and BTK inhibitors with epilepsy.

ABSTRACT:

Background

Multiple lines of evidence suggest a role of inflammation in epilepsy. Seizure incidence in patients with multiple sclerosis (MS) is twofold to threefold higher than the age-matched general population.

Objectives

To explore the association of MS disease-modifying therapies (DMTs) and FDA-approved Bruton tyrosine kinase inhibitors (for lymphocytic malignancies) with the occurrence of epilepsy using the US Food and Drug Administration Adverse Event Reporting System (FAERS) database.

Design

Secondary analysis of the FAERS database.

Methods

We conducted a disproportionality analysis of FAERS between 2003-Q4 and 2023-Q3. MS DMTs and the Bruton tyrosine kinase inhibitor, ibrutinib, were included in the analysis. An inverse association was defined by a 95%

SUBMITTER: Shirani A 

PROVIDER: S-EPMC11456174 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature